BACKGROUND: Pseudoprogression (PsP) occurs at a higher rate in glioblastoma multiforme with a methylated MGMT promoter-a subset with increased sensitivity to chemoradiotherapy and better overall prognosis. In oligodendroglioma (OG) and oligoastrocytoma (OA), presence of 1p/19q codeletions is highly predictive of response to treatment and is often associated with the methylated MGMT promoter; hence, this study queries whether the presence of 1p/19q codeletions in OG/OA correlates with a higher rate of PsP following therapy. METHODS: A retrospective analysis was performed on all OG/OA in a database of patients with brain tumors who underwent resection of their tumor since 1998. Eighty-eight cases (37 with and 51 without 1p/19q codeletions) met inclusion criteria, and their patient data were analyzed to determine whether the presence of 1p/19q codeletions was associated with PsP and survival. RESULTS: OG/OA (World Health Organization grades II and III) with 1p/19q codeletions had a significantly improved survival (P = .041). Multivariate analysis found that PsP occurred less frequently in OG/OA with 1p/19q codeletions compared with tumors without codeletions (odds ratio, 0.047; 95% confidence interval, 0.005-0.426; P = .0066). The rate of PsP was 19% for the entire cohort, 31% for tumors without codeletions, and 3% for tumors with codeletions. When early posttreatment contrast enhancement developed in tumors with 1p/19q codeletions, it occurred exclusively in tumors that were histologically OA and not OG. CONCLUSION: Codeletions of 1p/19q are a marker of good prognosis but are unexpectedly associated with a lower likelihood of PsP. PsP does not correlate with sensitivity to treatment and improved survival in OG/OA.
BACKGROUND: Pseudoprogression (PsP) occurs at a higher rate in glioblastoma multiforme with a methylated MGMT promoter-a subset with increased sensitivity to chemoradiotherapy and better overall prognosis. In oligodendroglioma (OG) and oligoastrocytoma (OA), presence of 1p/19q codeletions is highly predictive of response to treatment and is often associated with the methylated MGMT promoter; hence, this study queries whether the presence of 1p/19q codeletions in OG/OA correlates with a higher rate of PsP following therapy. METHODS: A retrospective analysis was performed on all OG/OA in a database of patients with brain tumors who underwent resection of their tumor since 1998. Eighty-eight cases (37 with and 51 without 1p/19q codeletions) met inclusion criteria, and their patient data were analyzed to determine whether the presence of 1p/19q codeletions was associated with PsP and survival. RESULTS: OG/OA (World Health Organization grades II and III) with 1p/19q codeletions had a significantly improved survival (P = .041). Multivariate analysis found that PsP occurred less frequently in OG/OA with 1p/19q codeletions compared with tumors without codeletions (odds ratio, 0.047; 95% confidence interval, 0.005-0.426; P = .0066). The rate of PsP was 19% for the entire cohort, 31% for tumors without codeletions, and 3% for tumors with codeletions. When early posttreatment contrast enhancement developed in tumors with 1p/19q codeletions, it occurred exclusively in tumors that were histologically OA and not OG. CONCLUSION: Codeletions of 1p/19q are a marker of good prognosis but are unexpectedly associated with a lower likelihood of PsP. PsP does not correlate with sensitivity to treatment and improved survival in OG/OA.
Authors: D Maintz; K Fiedler; J Koopmann; B Rollbrocker; S Nechev; D Lenartz; A P Stangl; D N Louis; J Schramm; O D Wiestler; A von Deimling Journal: J Neuropathol Exp Neurol Date: 1997-10 Impact factor: 3.685
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Wolf Mueller; Christian Hartmann; Annegret Hoffmann; Wolfgang Lanksch; Jürgen Kiwit; Jörg Tonn; Julian Veelken; Johannes Schramm; Michael Weller; Otmar D Wiestler; David N Louis; Andreas von Deimling Journal: Am J Pathol Date: 2002-07 Impact factor: 4.307
Authors: Yoshikazu Okamoto; Pier-Luigi Di Patre; Christoph Burkhard; Sonja Horstmann; Benjamin Jourde; Michael Fahey; Danielle Schüler; Nicole M Probst-Hensch; M Gazi Yasargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: Acta Neuropathol Date: 2004-04-28 Impact factor: 17.088
Authors: Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger Journal: Int J Cancer Date: 2005-01-20 Impact factor: 7.396
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Andrew L Lin; Michael White; Michelle M Miller-Thomas; Robert S Fulton; Christina I Tsien; Keith M Rich; Robert E Schmidt; David D Tran; Sonika Dahiya Journal: J Neurooncol Date: 2016-10-04 Impact factor: 4.130
Authors: Sophie E van West; Hein G de Bruin; Bart van de Langerijt; Annemarie T Swaak-Kragten; Martin J van den Bent; Walter Taal Journal: Neuro Oncol Date: 2017-05-01 Impact factor: 12.300
Authors: Ethan B Ludmir; Anita Mahajan; Arnold C Paulino; Jeremy Y Jones; Leena M Ketonen; Jack M Su; David R Grosshans; Mary Frances McAleer; Susan L McGovern; Yasmin A Lassen-Ramshad; Adekunle M Adesina; Robert C Dauser; Jeffrey S Weinberg; Murali M Chintagumpala Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Derek S Tsang; Erin S Murphy; John T Lucas; Pagona Lagiou; Sahaja Acharya; Thomas E Merchant Journal: J Neurooncol Date: 2017-07-27 Impact factor: 4.130
Authors: Julianna K Bronk; Nandita Guha-Thakurta; Pamela K Allen; Anita Mahajan; David R Grosshans; Susan L McGovern Journal: Clin Transl Radiat Oncol Date: 2018-01-12